Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
Evoke Pharma, Inc. (EVOK)
Last evoke pharma, inc. earnings: 11/7 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
evokepharmainc.gcs-web.com/investor-overview
Company Research
Source: GlobeNewswire
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, underscores its commitment to patients and healthcare providers managing gastroparesis in light of FDA’s recent update regarding domperidone supply. As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI® (metoclopramide) is uniquely positioned to address the ongoing needs of patients facing challenges with alternative therapies. The FDA recently posted: “Efforts made in the interim to identify an alternative s
Show less
Read more
Impact Snapshot
Event Time:
EVOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVOK alerts
High impacting Evoke Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
EVOK
News
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends [Yahoo! Finance]Yahoo! Finance
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Evoke Pharma, Inc. (NASDAQ: EVOK) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
EVOK
Sec Filings
- 11/22/24 - Form 424B5
- 11/15/24 - Form 3
- 11/14/24 - Form SC
- EVOK's page on the SEC website